Cost Considerations in the Drug Treatment of Hypertension

Gespeichert in:

Autor*in:	Kaplan, Norman M. [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	1996

Schlagwörter:	Diltiazem Calcium Antagonist Joint National Committee Texas Southwestern Medical Calcium Antagonist Diltiazem

Übergeordnetes Werk:	Enthalten in: PharmacoEconomics - Berlin [u.a.] : Springer, 1992, 9(1996), 4 vom: Apr., Seite 283-285
Übergeordnetes Werk:	volume:9 ; year:1996 ; number:4 ; month:04 ; pages:283-285

Links:	Volltext

DOI / URN:	10.2165/00019053-199609040-00001

Katalog-ID:	SPR033324123

Internformat


LEADER	01000caa a22002652 4500
001	SPR033324123
003	DE-627
005	20230519232555.0
007	cr uuu---uuuuu
008	201007s1996 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.2165/00019053-199609040-00001 \|2 doi
035			\|a (DE-627)SPR033324123
035			\|a (SPR)00019053-199609040-00001-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q ASE
084			\|a 44.40 \|2 bkl
100	1		\|a Kaplan, Norman M. \|e verfasserin \|4 aut
245	1	0	\|a Cost Considerations in the Drug Treatment of Hypertension
264		1	\|c 1996
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
650		4	\|a Diltiazem \|7 (dpeaa)DE-He213
650		4	\|a Calcium Antagonist \|7 (dpeaa)DE-He213
650		4	\|a Joint National Committee \|7 (dpeaa)DE-He213
650		4	\|a Texas Southwestern Medical \|7 (dpeaa)DE-He213
650		4	\|a Calcium Antagonist Diltiazem \|7 (dpeaa)DE-He213
773	0	8	\|i Enthalten in \|t PharmacoEconomics \|d Berlin [u.a.] : Springer, 1992 \|g 9(1996), 4 vom: Apr., Seite 283-285 \|w (DE-627)327645717 \|w (DE-600)2043876-X \|x 1179-2027 \|7 nnns
773	1	8	\|g volume:9 \|g year:1996 \|g number:4 \|g month:04 \|g pages:283-285
856	4	0	\|u https://dx.doi.org/10.2165/00019053-199609040-00001 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a SSG-OPC-PHA
912			\|a SSG-OPC-ASE
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2190
936	b	k	\|a 44.40 \|q ASE
951			\|a AR
952			\|d 9 \|j 1996 \|e 4 \|c 04 \|h 283-285

Indexfelder

author_variant	n m k nm nmk
matchkey_str	article:11792027:1996----::otosdrtosnhdutetet
hierarchy_sort_str	1996
bklnumber	44.40
publishDate	1996
allfields	10.2165/00019053-199609040-00001 doi (DE-627)SPR033324123 (SPR)00019053-199609040-00001-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Kaplan, Norman M. verfasserin aut Cost Considerations in the Drug Treatment of Hypertension 1996 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Diltiazem (dpeaa)DE-He213 Calcium Antagonist (dpeaa)DE-He213 Joint National Committee (dpeaa)DE-He213 Texas Southwestern Medical (dpeaa)DE-He213 Calcium Antagonist Diltiazem (dpeaa)DE-He213 Enthalten in PharmacoEconomics Berlin [u.a.] : Springer, 1992 9(1996), 4 vom: Apr., Seite 283-285 (DE-627)327645717 (DE-600)2043876-X 1179-2027 nnns volume:9 year:1996 number:4 month:04 pages:283-285 https://dx.doi.org/10.2165/00019053-199609040-00001 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 9 1996 4 04 283-285
spelling	10.2165/00019053-199609040-00001 doi (DE-627)SPR033324123 (SPR)00019053-199609040-00001-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Kaplan, Norman M. verfasserin aut Cost Considerations in the Drug Treatment of Hypertension 1996 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Diltiazem (dpeaa)DE-He213 Calcium Antagonist (dpeaa)DE-He213 Joint National Committee (dpeaa)DE-He213 Texas Southwestern Medical (dpeaa)DE-He213 Calcium Antagonist Diltiazem (dpeaa)DE-He213 Enthalten in PharmacoEconomics Berlin [u.a.] : Springer, 1992 9(1996), 4 vom: Apr., Seite 283-285 (DE-627)327645717 (DE-600)2043876-X 1179-2027 nnns volume:9 year:1996 number:4 month:04 pages:283-285 https://dx.doi.org/10.2165/00019053-199609040-00001 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 9 1996 4 04 283-285
allfields_unstemmed	10.2165/00019053-199609040-00001 doi (DE-627)SPR033324123 (SPR)00019053-199609040-00001-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Kaplan, Norman M. verfasserin aut Cost Considerations in the Drug Treatment of Hypertension 1996 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Diltiazem (dpeaa)DE-He213 Calcium Antagonist (dpeaa)DE-He213 Joint National Committee (dpeaa)DE-He213 Texas Southwestern Medical (dpeaa)DE-He213 Calcium Antagonist Diltiazem (dpeaa)DE-He213 Enthalten in PharmacoEconomics Berlin [u.a.] : Springer, 1992 9(1996), 4 vom: Apr., Seite 283-285 (DE-627)327645717 (DE-600)2043876-X 1179-2027 nnns volume:9 year:1996 number:4 month:04 pages:283-285 https://dx.doi.org/10.2165/00019053-199609040-00001 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 9 1996 4 04 283-285
allfieldsGer	10.2165/00019053-199609040-00001 doi (DE-627)SPR033324123 (SPR)00019053-199609040-00001-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Kaplan, Norman M. verfasserin aut Cost Considerations in the Drug Treatment of Hypertension 1996 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Diltiazem (dpeaa)DE-He213 Calcium Antagonist (dpeaa)DE-He213 Joint National Committee (dpeaa)DE-He213 Texas Southwestern Medical (dpeaa)DE-He213 Calcium Antagonist Diltiazem (dpeaa)DE-He213 Enthalten in PharmacoEconomics Berlin [u.a.] : Springer, 1992 9(1996), 4 vom: Apr., Seite 283-285 (DE-627)327645717 (DE-600)2043876-X 1179-2027 nnns volume:9 year:1996 number:4 month:04 pages:283-285 https://dx.doi.org/10.2165/00019053-199609040-00001 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 9 1996 4 04 283-285
allfieldsSound	10.2165/00019053-199609040-00001 doi (DE-627)SPR033324123 (SPR)00019053-199609040-00001-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Kaplan, Norman M. verfasserin aut Cost Considerations in the Drug Treatment of Hypertension 1996 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Diltiazem (dpeaa)DE-He213 Calcium Antagonist (dpeaa)DE-He213 Joint National Committee (dpeaa)DE-He213 Texas Southwestern Medical (dpeaa)DE-He213 Calcium Antagonist Diltiazem (dpeaa)DE-He213 Enthalten in PharmacoEconomics Berlin [u.a.] : Springer, 1992 9(1996), 4 vom: Apr., Seite 283-285 (DE-627)327645717 (DE-600)2043876-X 1179-2027 nnns volume:9 year:1996 number:4 month:04 pages:283-285 https://dx.doi.org/10.2165/00019053-199609040-00001 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 9 1996 4 04 283-285
language	English
source	Enthalten in PharmacoEconomics 9(1996), 4 vom: Apr., Seite 283-285 volume:9 year:1996 number:4 month:04 pages:283-285
sourceStr	Enthalten in PharmacoEconomics 9(1996), 4 vom: Apr., Seite 283-285 volume:9 year:1996 number:4 month:04 pages:283-285
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Diltiazem Calcium Antagonist Joint National Committee Texas Southwestern Medical Calcium Antagonist Diltiazem
dewey-raw	610
isfreeaccess_bool	false
container_title	PharmacoEconomics
authorswithroles_txt_mv	Kaplan, Norman M. @@aut@@
publishDateDaySort_date	1996-04-01T00:00:00Z
hierarchy_top_id	327645717
dewey-sort	3610
id	SPR033324123
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR033324123</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519232555.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1996 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00019053-199609040-00001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR033324123</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00019053-199609040-00001-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kaplan, Norman M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cost Considerations in the Drug Treatment of Hypertension</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1996</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Diltiazem</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Calcium Antagonist</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Joint National Committee</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Texas Southwestern Medical</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Calcium Antagonist Diltiazem</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">PharmacoEconomics</subfield><subfield code="d">Berlin [u.a.] : Springer, 1992</subfield><subfield code="g">9(1996), 4 vom: Apr., Seite 283-285</subfield><subfield code="w">(DE-627)327645717</subfield><subfield code="w">(DE-600)2043876-X</subfield><subfield code="x">1179-2027</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:1996</subfield><subfield code="g">number:4</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:283-285</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00019053-199609040-00001</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">1996</subfield><subfield code="e">4</subfield><subfield code="c">04</subfield><subfield code="h">283-285</subfield></datafield></record></collection>
author	Kaplan, Norman M.
spellingShingle	Kaplan, Norman M. ddc 610 bkl 44.40 misc Diltiazem misc Calcium Antagonist misc Joint National Committee misc Texas Southwestern Medical misc Calcium Antagonist Diltiazem Cost Considerations in the Drug Treatment of Hypertension
authorStr	Kaplan, Norman M.
ppnlink_with_tag_str_mv	@@773@@(DE-627)327645717
format	electronic Article
dewey-ones	610 - Medicine & health
delete_txt_mv	keep
author_role	aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	1179-2027
topic_title	610 ASE 44.40 bkl Cost Considerations in the Drug Treatment of Hypertension Diltiazem (dpeaa)DE-He213 Calcium Antagonist (dpeaa)DE-He213 Joint National Committee (dpeaa)DE-He213 Texas Southwestern Medical (dpeaa)DE-He213 Calcium Antagonist Diltiazem (dpeaa)DE-He213
topic	ddc 610 bkl 44.40 misc Diltiazem misc Calcium Antagonist misc Joint National Committee misc Texas Southwestern Medical misc Calcium Antagonist Diltiazem
topic_unstemmed	ddc 610 bkl 44.40 misc Diltiazem misc Calcium Antagonist misc Joint National Committee misc Texas Southwestern Medical misc Calcium Antagonist Diltiazem
topic_browse	ddc 610 bkl 44.40 misc Diltiazem misc Calcium Antagonist misc Joint National Committee misc Texas Southwestern Medical misc Calcium Antagonist Diltiazem
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	PharmacoEconomics
hierarchy_parent_id	327645717
dewey-tens	610 - Medicine & health
hierarchy_top_title	PharmacoEconomics
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)327645717 (DE-600)2043876-X
title	Cost Considerations in the Drug Treatment of Hypertension
ctrlnum	(DE-627)SPR033324123 (SPR)00019053-199609040-00001-e
title_full	Cost Considerations in the Drug Treatment of Hypertension
author_sort	Kaplan, Norman M.
journal	PharmacoEconomics
journalStr	PharmacoEconomics
lang_code	eng
isOA_bool	false
dewey-hundreds	600 - Technology
recordtype	marc
publishDateSort	1996
contenttype_str_mv	txt
container_start_page	283
author_browse	Kaplan, Norman M.
container_volume	9
class	610 ASE 44.40 bkl
format_se	Elektronische Aufsätze
author-letter	Kaplan, Norman M.
doi_str_mv	10.2165/00019053-199609040-00001
dewey-full	610
title_sort	cost considerations in the drug treatment of hypertension
title_auth	Cost Considerations in the Drug Treatment of Hypertension
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190
container_issue	4
title_short	Cost Considerations in the Drug Treatment of Hypertension
url	https://dx.doi.org/10.2165/00019053-199609040-00001
remote_bool	true
ppnlink	327645717
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.2165/00019053-199609040-00001
up_date	2024-07-03T17:56:52.943Z
_version_	1803581561710313472
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR033324123</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519232555.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1996 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00019053-199609040-00001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR033324123</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00019053-199609040-00001-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kaplan, Norman M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cost Considerations in the Drug Treatment of Hypertension</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1996</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Diltiazem</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Calcium Antagonist</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Joint National Committee</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Texas Southwestern Medical</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Calcium Antagonist Diltiazem</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">PharmacoEconomics</subfield><subfield code="d">Berlin [u.a.] : Springer, 1992</subfield><subfield code="g">9(1996), 4 vom: Apr., Seite 283-285</subfield><subfield code="w">(DE-627)327645717</subfield><subfield code="w">(DE-600)2043876-X</subfield><subfield code="x">1179-2027</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:1996</subfield><subfield code="g">number:4</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:283-285</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00019053-199609040-00001</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">1996</subfield><subfield code="e">4</subfield><subfield code="c">04</subfield><subfield code="h">283-285</subfield></datafield></record></collection>
score	7.398505

Nicht das Richtige dabei?

Schreiben Sie uns!

Cost Considerations in the Drug Treatment of Hypertension

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?